알펠리십(BYL-719) 투여량 mg/kg/일 QD,SMILES,"노출 AUC0-24hr, D14 (μM hr, 전체/자유)","노출 Cmax D14 (μM, 전체/자유)","노출  Cmin D14 (μM, 전체)","다중 노출* (전체/자유, AUC)","CD69에 대한 다중 노출 IC₅₀ (전체, Cₘᵢₙ)",임상 증상,임상 병리학+,조직 병리학+
3,C(C)(C)(c1cc(-c2sc(NC(=O)N3CCC[C@H]3C(N)=O)nc2C)ccn1)C(F)(F)F,14/1.0,1.97/0.14,0.2,0.2x/0.2x,0.3x,-,-,-
10,C(C)(C)(c1cc(-c2sc(NC(=O)N3CCC[C@H]3C(N)=O)nc2C)ccn2)C(F)(F)F,31.7/2.3,3.58/0.26,0.62,0.4x/0.4x,1.0x,-,↑피브리노겐,GI 염증: 호중구가 대장에 침투
30,C(C)(C)(c1cc(-c2sc(NC(=O)N3CCC[C@H]3C(N)=O)nc2C)ccn3)C(F)(F)F,160/11.5,20.6/1.5,1.25,2.2x/2.0x,2.0x,"↓식욕, 약 10%↓BW",↑호중구↑단핵구↑글로블린↑피브리노겐,"림프 고갈: 흉선, 림프절, GALT GI 염증: 호중구가 대장 및 소장에 침투; 직장 궤양"
